FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

SS-31

Elamipretide / MTP-131 / Bendavia

Longevity & Anti-Aging

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

작용 메커니즘

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Clinical trial protocols used 0.25mg/kg/hour IV infusion or 40mg daily subcutaneous injection. Research protocols use 1-5mg daily subcutaneously. Treatment duration varies by indication (4 weeks to 48 weeks in trials).

연구 노트

Clinical Research Status

SS-31 (Elamipretide) has advanced through multiple Phase II and Phase III clinical trials, most notably the TAZPOWER trial for Barth syndrome and the MMPOWER trials for primary mitochondrial myopathy. The FDA granted Fast Track designation for Barth syndrome, though the compound has faced regulatory setbacks with initial NDA submissions requiring additional data. Stealth BioTherapeutics continues clinical development programs targeting heart failure with reduced ejection fraction and dry age-related macular degeneration.

Key Published Findings

In the TAZPOWER Phase II trial, elamipretide demonstrated improvements in 6-minute walk test distance and patient-reported outcomes in Barth syndrome patients over 12 weeks of subcutaneous administration. Preclinical studies have shown SS-31 reduces mitochondrial ROS production by 50-75%, improves ATP synthesis, and prevents cardiolipin peroxidation in ischemia-reperfusion models. Research in aged mice demonstrated that SS-31 treatment reversed age-related declines in skeletal muscle mitochondrial energetics and improved exercise tolerance within one hour of administration.

Safety Profile

SS-31 has demonstrated good tolerability in clinical trials at subcutaneous doses of 4mg and 40mg daily, with injection site reactions being the most common adverse event. Serious adverse events in trials have been infrequent and generally not attributed to the drug. The peptide has a favorable pharmacokinetic profile with rapid absorption, short half-life requiring daily dosing, and no evidence of accumulation or organ toxicity in long-term administration studies.

Drug Interactions & Contraindications

No significant drug-drug interactions have been identified in clinical studies to date, likely due to SS-31's mechanism of action at the mitochondrial membrane rather than via enzymatic pathways. The compound does not appear to interact with cytochrome P450 enzymes or common drug transporters. Caution may be warranted in patients taking other mitochondrial-targeted compounds, though formal interaction studies are limited.

Comparison to Related Compounds

Unlike CoQ10 and MitoQ which require mitochondrial membrane potential for uptake, SS-31 concentrates in mitochondria independent of membrane potential, making it effective even in damaged or dysfunctional mitochondria. MitoQ is a ubiquinone-based antioxidant targeting the matrix, while SS-31 specifically targets the inner membrane cardiolipin interface. SS-31's mechanism of stabilizing cardiolipin microdomains is fundamentally different from traditional antioxidants, addressing structural rather than purely redox-related mitochondrial dysfunction.

Community Observations

Research peptide users report noticeable improvements in exercise capacity and subjective energy levels within the first week of subcutaneous SS-31 administration at 2-5mg daily. The compound has gained significant interest in the longevity community due to preclinical data showing rapid reversal of age-related mitochondrial decline. Users note that SS-31 is relatively expensive and difficult to source compared to other peptides, limiting widespread adoption outside clinical trial settings.

반감기

~4-6 hours

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C. Protect from light.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (in clinical trials)

또는 알려진 이름으로

ElamipretideMTP-131Bendavia

자주 묻는 질문

SS-31란 무엇인가요?

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

SS-31는 어떻게 작용하나요?

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

SS-31의 미국 규제 현황은 어떤가요?

Research chemical (in clinical trials)

SS-31의 반감기는 얼마인가요?

~4-6 hours

SS-31의 다른 이름은 무엇인가요?

Elamipretide, MTP-131, Bendavia

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기